15 May 2020 6:30 BST
AstraZeneca can confirm that it is in discussions with the US Government on expanding potential supply for the US as part of its previously announced agreement for the development and worldwide manufacturing and distribution of Oxford University’s potential recombinant adenovirus vaccine known as ChAdOx1 nCoV-19, aimed at preventing COVID-19 infection from SARS-CoV-2.
The Company remains committed to separate parallel supply agreements to ensure broad and equitable supply throughout the world at no profit. In particular, the Company is working on additional supply chains for Europe and other parts of the world and is engaged in discussions with global organisations such as the Coalition for Epidemic Preparedness Innovations (CEPI) so every country around the world can benefit from the potential vaccine.
In the UK, the Company is progressing at pace with the development and manufacturing of the potential vaccine.
[Additionally, AstraZeneca has also had discussions with the US Government to support its COVID-19 monoclonal antibody programme. Will only include if also mentioned in the WH press briefing].
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory and Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
